Scientists reveal the ‘perfect' male body type
Forget chiselled abs and ultra-lean physiques, researchers have found that 'dad bods,' with their softer edges and a bit of extra padding, are actually the gold standard for male attractiveness.
The study, published by researchers from the Chinese Academy of Sciences in Personality and Individual Differences, even put forward theories as to why people with this kind of physique are the most appealing.
The study methodology
The study involved 283 participants from China, Lithuania, and the UK.
Each person was shown 15 black-and-white photos of men with different body mass indexes (BMIs).
BMI is a calculation that uses height and weight to determine whether someone is underweight, of a healthy weight, overweight, or obese.
The photos included men with BMIs ranging from 20.1 to 33.7.
Faces were blurred to focus solely on body shape, and participants were asked to rank the images from least to most attractive.
The results showed that the most appealing male bodies had a BMI between 23 and 27.
Specifically, peak attractiveness was linked to a BMI of 23.4 in China, 23.0 in Lithuania, and 26.6 in the UK.
For context, in Australia, a 'healthy' BMI for adults generally falls between 18.5 and 24.9, with those between 25 and 29.9 considered 'overweight'.
Therefore, the most attractive bodies weren't those who were skinny or very lean, but rather those with a few extra kilos.
What this means
Although the physical findings are interesting, the researchers were more intrigued by the 'why' behind the results.
'Body fat (adiposity) may be important because it is linked closely (inversely) to circulating testosterone levels and is therefore a better indicator of mate 'quality',' the researchers said.
Basically, a mid-range BMI aligns with optimal survival and reproductive fitness.
'The most attractive BMI in males was close to the predicted level maximising survival,' the study explained.
So, if you've been skipping the gym for the occasional pint and schnitty, science suggests you might be onto something.
But for women, the same can't be said.
The researchers found in earlier work that males who judge females believe that being thinner than the 'evolutionary optimal' is more attractive.
So while women might pick a partner based on their evolutionary advantages, men mainly just care about how their partner's look.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
3 hours ago
- News.com.au
Health Check: Amid headwinds, Nanosonics goes bells and whistles on core device
Nanosonics has launched tweaked versions of its Trophon medical probe steriliser Amplia shares soar a further 36% on pancreatic cancer promise Dimerix looks to broaden its repertoire Nanosonics (ASX:NAN) has launched updated iterations of its medical probe sterilising device Trophon, pending rollout of its all-new tool called Coris. The 'next generation' Trophon 3 has 40% faster cleaning cycles, with 'greater digital integration and the broadest traceability capabilities". The company has also launched Trophon 2 Plus, a tweaked version of an existing software upgrade for users of earlier Trophons. The company first commercialised the Trophons in 2009. Trophons clean ultrasound probes much more safely and reliably than traditional manual techniques. In mid-March the US Food & Drug Administration (FDA) approved the company's an all-new product Coris, for more fiddly flexible probes (such as for colonoscopies). The company expects to launch Coris in the US later this year. Nanosonics initially is launching the Trophon upgrades here and in the UK and Europe, with the FDA reviewing an approval submission. What the analysts think RBC Capital Markets analyst Craig Wong-Pan estimates only about 35% of the company's current US users have upgraded to a Trophon 2. "Therefore we believe there is a reasonable runway for further upgrade sales.' He's not sure whether the Trophon 3 features will convince enough hospitals to upgrade, given their budgetary pressures. 'Nonetheless, we believe the launch of these offerings is positive for Nanosonics, given the company has seen new competing products enter the ultrasound probe high level disinfection market.' RBC rates the company a 'hold' with a target price of $5. Meanwhile, broker Canaccord retains a 'buy' call, but has revised its target price from $5.74 to $5.15. The firm cites the impact of a competitor, Lumicare, which is not FDA approved but looks to be winning market share here. Canaccord expects Nanosonics to report 2024-25 revenue at the bottom of its cited $188.7 million to $193.8 million range. Amplia continues its winning ways One of the deadliest of tumours, pancreatic cancer is having its day in the sun courtesy of progress reports from Amplia (ASX:ATX) and OncoSil Medical (ASX:OSL). Amplia shares today vaulted a further 36%, having soared 25%, on Friday. That was after the company confirmed a 16 th 'partial response' in its phase 1b/2a advanced pancreatic cancer trial, called Accent. A confirmed partial response is when a tumour shrinks by more than 30% and the effect is sustained for two months or more. More to the point, Amplia earlier recorded two 'pathological complete responses' (PCRs). Rare in advanced pancreatic cancers, a PCR means there are no signs of cancer in tissue examined by a pathologist following surgical removal. Accent is evaluating Amplia's drug candidate narmafotinib, in combination with standard-of-care chemotherapies. Of the 55 patients enrolled, 20 of them remain on the trial so the company hopes for more positive responses. The trial is being conducted at seven sites in Australia and five sites in South Korea. Amplia shares have gained 330% since the start of the year. Oncosil completes trial enrolment Also on Friday, Oncosil said it had enrolled all 20 advanced pancreatic cancer patients in a phase I/II study of its eponymous targeted device. A novel brachytherapy for pancreatic and liver cancers, the treatment involves irradiating tumours via a direct injection, using endoscopic ultrasound guidance. Dubbed Pancosil, the study is investigating a novel percutaneous (through the skin) delivery for the spherical devices, guided by computed tomography. As investigator, The Amsterdam University Medical Center is conducting the study. Oncosil CEO Nigel Lange says the percutaneous approach could 'simplify administration and lower barriers to adoption, supporting wider market penetration and real-world clinical use'. The idea is not to cure the cancer, but reduce the tumors to the point where they are operable. Currently 30 countries have approved the device, including in the European Union, Britain, Turkey and Israel. The company should release preliminary Pancosil data in late 2025. Dimerix eyes other indications While the cashed-up Dimerix (ASX:DXB) remains focused on its phase III kidney disease program, it's eyeing secondary activities to broaden its portfolio. The company has raked in $65 million in upfront payments from four separate partnering deals for its lead indication, the regressive focal segmental glomerulosclerosis (FSGS). But not all the cash is needed to support the 286-patient phase III trial. 'Now that the funds have come in, we are in a very strong position and can turn attention to our pipeline,' CEO Dr Nina Webster says. She is working with the board on what program to pursue, but it will be 'in an area of high unmet need' and not too far from the company's expertise. 'Generally speaking, our competency is inflammatory disease and we understand rare diseases and kidneys well,' Webster says. We know for sure it won't be something like oncology injectables. Nor will it be diabetic kidney disease, which is much more prevalent than FSGS but a competitive field. In the meantime, Dimerix hopes it might be able to win accelerated FDA approval for FSGS, which the agency classes as an 'orphan' disease. … while PYC expands kidney disease trial Still on the topic of spuds. Following ethics approval, PYC Therapeutics (ASX:PYC) will advance to the second part of its safety and dosage study for polycystic kidney disease (PKD). PYC hopes its drug candidate, PYC-003 will address the underlying cause of PYC, the most prevalent monogenic disease in humans marked by extreme swelling of the organ. PYC will launch part B of the single ascending dose study of PKD patients, as well as escalating dosing to healthy volunteers. By combining existing ribonucleic acid (RNA) drug design with its proprietary delivery platform, PYC is developing precision therapies for patients with genetic diseases that have no treatment options. PYC's lead program is for the rare eye disease retinitis pigmentosa, but the company believes the kidney program shows much promise.
News.com.au
3 days ago
- News.com.au
Kate takes on major royal responsibility after deeply personal remarks about cancer battle
IN LONDON Just days after opening up about the challenges of adjusting to normalcy following cancer treatment, the Princess of Wales is taking on a major new royal duty. It's been announced that Kate will join Prince William in greeting French President Emmanual Macron and his wife, First Lady Brigitte Macron, as they arrive in the UK on Tuesday for their state visit. The pair will fly into RAF Northolt and then be hosted at Windsor Castle for their two-day trip, marking the first time the royal residence has been used over Buckingham Palace for such an occasion in more than a decade. The iconic central London palace is currently undergoing extensive refurbishments. Kate and William will also join the King and Queen in taking a carriage ride with the president and his wife through Windsor on Tuesday. That evening, they will be officially welcomed to Britain with a state banquet, although Kate's attendance is yet to be confirmed. The president is also set to address parliament and have lunch with British prime minister Keir Starmer and their wives, before being given a personal tour of items relating to France in the Royal Collection. The high-profile royal engagements come just a couple of weeks after Kate was forced to pull out of her scheduled appearance at Royal Ascot at the last minute. She had been listed in the official guide as travelling in the second carriage of the royal procession, alongside Prince William, after having to skip the 2024 event amid her cancer battle. Local media reported she was 'disappointed' at having to miss this year too, but was having to 'find the right balance as she fully returns to public facing engagements'. On Wednesday, Kate shared a harrowing insight into the realities of her health battle behind closed doors during a moving visit to a cancer treatment centre. She explained she'd had to put on a 'brave face' throughout and following her treatment, describing life afterwards as 'really difficult'. Kate also admitted she'd found it hard to 'function normally at home' as she recovered. Back in January, Kate revealed she was in remission from cancer, which she had first publicly disclosed last March. In September, she released an emotional video message, featuring personal footage of herself with William and their three children, opening up about the challenges they'd all been privately battling, but also proudly revealing she had completed her treatment.
News.com.au
3 days ago
- News.com.au
Scientists reveal the ‘perfect' male body type
It's a great day for those with a 'dad bod,' because according to a new study, it's the body type women find most attractive. Forget chiselled abs and ultra-lean physiques, researchers have found that 'dad bods,' with their softer edges and a bit of extra padding, are actually the gold standard for male attractiveness. The study, published by researchers from the Chinese Academy of Sciences in Personality and Individual Differences, even put forward theories as to why people with this kind of physique are the most appealing. The study methodology The study involved 283 participants from China, Lithuania, and the UK. Each person was shown 15 black-and-white photos of men with different body mass indexes (BMIs). BMI is a calculation that uses height and weight to determine whether someone is underweight, of a healthy weight, overweight, or obese. The photos included men with BMIs ranging from 20.1 to 33.7. Faces were blurred to focus solely on body shape, and participants were asked to rank the images from least to most attractive. The results showed that the most appealing male bodies had a BMI between 23 and 27. Specifically, peak attractiveness was linked to a BMI of 23.4 in China, 23.0 in Lithuania, and 26.6 in the UK. For context, in Australia, a 'healthy' BMI for adults generally falls between 18.5 and 24.9, with those between 25 and 29.9 considered 'overweight'. Therefore, the most attractive bodies weren't those who were skinny or very lean, but rather those with a few extra kilos. What this means Although the physical findings are interesting, the researchers were more intrigued by the 'why' behind the results. 'Body fat (adiposity) may be important because it is linked closely (inversely) to circulating testosterone levels and is therefore a better indicator of mate 'quality',' the researchers said. Basically, a mid-range BMI aligns with optimal survival and reproductive fitness. 'The most attractive BMI in males was close to the predicted level maximising survival,' the study explained. So, if you've been skipping the gym for the occasional pint and schnitty, science suggests you might be onto something. But for women, the same can't be said. The researchers found in earlier work that males who judge females believe that being thinner than the 'evolutionary optimal' is more attractive. So while women might pick a partner based on their evolutionary advantages, men mainly just care about how their partner's look.
